Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Launches New Office to Fuel SaMD Commercialization
April 6, 2021
- MHLW to Consider Ways to Address Listing Delays Linked to Off-Year Re-Pricing: Official
April 6, 2021
- Nichi-Iko’s Toyama Plant Gets Back Online as Suspension Order Lifted
April 6, 2021
- 1st Vaccine Doses to Be Delivered for Half of Elderly by May: Kono
April 5, 2021
- Ex-PMDA Inspector Urges Improvements in Japanese Inspection Systems after GMP Scandals
April 5, 2021
- Japan Mulls Expanding COVID-19 Vaccination Age to 12-15
April 5, 2021
- MHLW Calls for Thiola’s Priority Use for Cystinuria as Shortage Expected
April 2, 2021
- Neurosurgical Expert Eager to Carry Out Bridging Study of Cannabis-Derived Drug in Japan
April 2, 2021
- Japan Publishes Cost-Effectiveness Analysis Reports for Kymriah, Trelegy
April 1, 2021
- Japan to Research Duration of COVID-19 Vaccine Efficacy: Minister
March 31, 2021
- Label Revisions Ordered for Utemerin and More Drugs, 1st Update for Zolgensma
March 31, 2021
- 1.35% of Tokyo Residents Have Coronavirus Antibodies: MHLW
March 31, 2021
- Govt’s Drug Development Panel Adopts 5 Priority Topics for Discussion
March 31, 2021
- Govt to Set Up Taskforce to Spur Development of Japan-Made Vaccines
March 30, 2021
- Japan Gives Up on Setting New Generic Target by March as Manufacturing Scandals Weigh
March 30, 2021
- LDP League Submits Request to Reinstate HPV Vaccine Promotion
March 30, 2021
- MHLW Panel Approves List of “Stable Supply Medicines”; Pricing to Become Topic of Discussions
March 30, 2021
- Japan to Wade Deeper into Generic Industry Revamp in New Pharma Vision, Due Out Summer
March 29, 2021
- Govt Plans Switch to 6-Dose Syringes for Elderly “Sometime in May”: Kono
March 29, 2021
- 35.6% of Pfizer Vaccine Recipients Developed Fevers after 2nd Shot, Higher Incidence in Women: MHLW
March 29, 2021
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…